2014
DOI: 10.1093/infdis/jiu576
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus That of 7-Valent PCV (PCV7) Against Nasopharyngeal Colonization of Antibiotic-NonsusceptibleStreptococcus pneumoniae

Abstract: NCT00508742.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

2
43
1
3

Year Published

2016
2016
2023
2023

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 72 publications
(49 citation statements)
references
References 30 publications
2
43
1
3
Order By: Relevance
“…Published reports describe similar increases in these serotypes in children following PCV13 implementation. 17,22,31,[35][36][37][38] McElligot found serotype 35B to be among the leading source of penicillin non-susceptible pneumococci in both carriage and non-invasive pneumococcal infection in children in Ireland. 36 Cohen noted that serotypes 15B/C and 35B were among the non-PCV13 serotypes identified in carriage among children in France, with serotype 15B/C reaching the "emergent serotype" threshold of >5% in their study population.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Published reports describe similar increases in these serotypes in children following PCV13 implementation. 17,22,31,[35][36][37][38] McElligot found serotype 35B to be among the leading source of penicillin non-susceptible pneumococci in both carriage and non-invasive pneumococcal infection in children in Ireland. 36 Cohen noted that serotypes 15B/C and 35B were among the non-PCV13 serotypes identified in carriage among children in France, with serotype 15B/C reaching the "emergent serotype" threshold of >5% in their study population.…”
Section: Discussionmentioning
confidence: 99%
“…41 Furthermore, as serotypes 15B/C and 35B emerged, it became clear that many isolates are b-lactam resistant. 36,38,41 Strengths of this study include the prospective collection of a large number of nasopharyngeal samples from a high risk population for pneumococcal isolation. Limitations of this study include the low carriage rates resulting in low number of pneumococci isolated, limiting the generalizability of serotype and antibiotic susceptibility results and factors associate with carriage.…”
Section: Discussionmentioning
confidence: 99%
“…Reducing NP carriage decreases the transmission of VT S. pneumoniae, thereby driving the herd immunity effect observed in unvaccinated individuals where PCV immunization has been implemented [2] [4] [13]. Since most antibiotic non-susceptible S. pneumoniae serotypes are covered by PCV7 [14], the vaccine also decreases an-…”
Section: Introductionmentioning
confidence: 99%
“…El microorganismo recuperado con mayor frecuencia desde hemocultivos de niños con BO probable fue S. pneumoniae y como era de esperar, fue menos frecuente, aunque estadísticamente no significativo, en el grupo de niños protegidos. Estudios como el de Kaiser Permanente describe el gran impacto de la PCV7 en niños entre 3 y 36 meses ambulatorios con bacteriemia por S. pneumoniae, con marcado descenso de su incidencia en Carolina del Norte [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27] . En nuestro estudio es destacable que los pacientes protegidos y parcialmente protegidos, presentaron ENI por serotipos no vaccinales, mientras que los no protegidos tuvieron infecciones tanto por serotipos vaccinales como no vaccinales.…”
Section: Discussionunclassified
“…La primera vacuna conjugada disponible internacionalmente fue la 7-valente (PCV7), que contiene a los serotipos 4, 6B, 9V, 14, 18C, 19F y 23F 8,10 . Posteriormente se desarrollaron vacunas con mayor número de serotipos, la PCV 10-valente (PCV10), que agregó a los serotipos 1, 5 y 7F y la PCV13-valente (PCV13), que además de los mencionados sumó los serotipos 3, 6A, 19A 8,[10][11][12] . Los serotipos 6A y 19A corresponden a los denominados serotipos relacionados a PCV10, los que a pesar de no estar incluidos en la vacuna, alcanzarían un grado de protección cruzada a través de los serotipos 6B y 19F, respectivamente 13.14 .…”
Section: Introductionunclassified